Treatment-Resistant Depression Market

Treatment-Resistant Depression Market Size Survey Report – In a Glance

As per the survey report on global Treatment-resistant depression market, the market is projected to foresee a CAGR of 10.6% between 2024-2033, and further generate a market size of USD 4.5 billion revenue by the end of 2033. In the year 2024, the market size was valued at USD 2.1 billion revenue.

• The global Treatment-resistant depression market is projected to grow on account of the rising rates of depression.
• In Japan, the Treatment-resistant depression market growth can be attributed to the rising psychological disorders.
• KDMI analyst’s growth analysis foresees harmful consequences of TRD medications to challenge the market growth.
• North America, having the highest market share in the Treatment-resistant depression market, is projected to dominate the global market.

Treatment-Resistant Depression Market Analysis

Treatment-resistant depression (TRD) is a severe depressive mood disorder where standard antidepressants remain unresponsive and fail to ease or improve symptoms after multiple proper antidepressant trials. In such conditions, the patient may require alternative approaches like electroconvulsive therapy (ECT) or neuromodulation to manage the symptoms. Depression is not a recent issue and has been around for centuries. Feelings of sadness, fear, or hopelessness have been part of human life throughout the ages. In recent times, the rising rates of depression are likely to contribute to the expansion of the TRD market. Research suggests that approximately 5% of adults worldwide struggle with depression with women experiencing it more frequently than men. Therefore, an increasing number of depression cases heightens the demand for new treatment options, ultimately stimulating the global TRD market. Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), are some of the significant parties in the global market for Treatment-resistant depression .

Analyst’s Observation on Japan Treatment-Resistant Depression Market Survey

The Japanese population is known for its longest life expectancy. Although most research focuses on physical well-being, there has been a drastic rise in mental health issues like anxiety, addiction, and suicide within the country over the years. However, the market growth for treatment-resistant depression (TRD) can be directly linked to the rising psychological disorders as the growing rates of mental disorders demand advanced treatments, steering the overall market. Moreover, the COVID-19 pandemic stripped people of their daily routines and left lasting effects. The prolonged crisis particularly affected the women and youth, leading to shifts in suicide trends. A report by the OECD stated that the country’s depression rate reached 17.3% which is twice the earlier figure, with suicide rates increasing for the first time in 11 years. Sumitomo Pharma, Otsuka Pharmaceutical, Sage Therapeutics, are some of the significant parties in the market for Treatment-resistant depression in Japan.

Treatment-Resistant Depression Market Growth Drivers and Challenges

Growth Drivers

Greater public awareness of psychological well-being:

Due to stigma or lack of awareness, many people miss out on seeking necessary mental health care and some are even unaware of its treatment options. In addition, mental illnesses also lead to economic strain, with work-related losses surpassing the direct costs of healthcare. Mental health awareness helps reduce this stigma, ensuring better physical, emotional, cognitive, and social health of an individual. Findings suggest that across the world, mental health disorders account for one-sixth of all years lived with a disability; with severely affected individuals having 10-20 years shorter lifespan. Hence, greater public awareness of psychological well-being including treatment-resistant depression (TRD) has lowered stigma among patients, resulting in increased help-seeking. This cultural shift drives the global TRD market by encouraging more people to explore treatment solutions and increasing the potential patient pool.

Progress in TRD treatment methods:

There have been major advancements made in depression therapy in the last two decades. As depression is unique to each person, more targeted antidepressants with minimal side effects are being formulated and combined in innovative ways. Coping with depression symptoms is tough, particularly for those battling with treatment-resistant depression (TRD) which is a long-lasting and severe form of depression. Fortunately, promising new treatments like ketamine are changing the landscape, providing fast and effective relief from severe depression. However, progress in TRD treatments like advanced pharmacological solutions and innovative neuromodulation approaches are influencing the global TRD market positively. These breakthrough therapies or medications offer new hope for patients who remain unresponsive to traditional treatments and also address the unmet needs of patients.

Restraints

Harmful consequences of TRD medications:

TRD drugs may lead to intense adverse reactions and contain substantial health risks, consisting of cognitive challenges, potential addiction, and persistent health complications. These unfavourable consequences of TRD medications decrease its adoption rates and reduce patient adherence, limiting the treatment demand and discouraging healthcare professionals, eventually restraining the development of the TRD market globally.

High-priced TRD treatment:

The high pricing of TRD treatments is significantly slowing the growth of the TRD market. Costly TRD medications or drugs block its global distribution, hinder affordability, and result in poor patient adherence. These factors limit the overall market reach and place a heavy financial burden on healthcare systems, collectively slowing down the TRD market growth and development.

Treatment-Resistant Depression Market Segmentation

Our experts at KD Market Insights have segmented the global Treatment-resistant depression market research report as:

Treatment-Resistant Depression Market Regional Synopsis

North America is at the forefront of the treatment-resistant depression (TRD) market and is majorly driven by the market presence of major firms and a surge in sanctioned drugs for depression treatment. Moreover, the progressive healthcare systems, increased awareness among the public and favorable government initiatives in Canada and the United States further fuel the market within the region. The United States holds the largest share of the regional treatment-resistant depression (TRD) market within the given period because of the growing prevalence of mental disorders, increased rate of drugs adoption, and strong distribution channels. Anxiety and depression rank among the most frequently diagnosed psychological conditions experienced by adults in the United States.

Asia-Pacific (APAC) is encountering the quickest market surge during the forecasted period. The region functions as a central point for pharmaceutical businesses. This is mainly due to expansive distribution channels and trade connections. Furthermore, the market is also steered by the increasing use of generic drugs, consumer demands, economic expansion and progressing healthcare infrastructure. India is also upgrading the treatment-resistant depression (TRD) market due to its massive population, heightened depression rates, fast economic progression, and strengthened healthcare systems. In addition to that, Japan’s economic progress is likely to expand at a rate beyond its expected growth capacity due to its increasing mental illness cases. China is also contributing a significant part to the regional market. It has implemented the world’s largest planned urban transformation program, thereby, promoting healthcare development. Also, numerous policies have supported its overall healthcare framework and economic growth goals.

In Europe, the existence of government organizations supporting healthcare development is mainly expected to drive treatment-resistant depression (TRD) market expansion in the coming future. Moreover, the UK is at the forefront of the development of the market in the region due to its rising depression cases. Various factors are responsible for the market evolution in the area such as the continuous research on innovative drugs, heightened focus on personal wellness, and expanding market supply of medical solutions. Apart from these, due to surging sedentary lifestyles & bad food habits, growing awareness about wellness, and increasing accessibility of treatment & medications are some of the crucial factors for steering the market growth in Middle East & Latin America.

As per our analysts at KD Market Insights, the following five players lead the North America Treatment-resistant depression market growth:

• Eli Lilly and Company
• Mylan N.V.
• Pfizer Inc.
• AbbVie Inc.
• Perrigo Company Plc.

Treatment-Resistant Depression Market Competitive Landscape

Some of the key players who top the global Treatment-resistant depression market share:

• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Hikma Pharmaceuticals plc (U.K.)
• Aurobindo Pharma (India)
• AbbVie Inc. (U.S.)
• Melinta Therapeutics, Inc (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Lupin (India)
• Perrigo Company plc (U.S.)
• Johnson & Johnson Services, Inc (U.S.)
• Sun Pharmaceutical Industries Ltd.(India)
• Amneal Pharmaceuticals LLC. (U.S.)
• Zydus Group (India)
• Teva Pharmaceutical Industries Ltd (Israel)
• Endo Pharmaceuticals plc (Ireland)
• Currax Pharmaceuticals LLC (U.S.)

1. Executive Summary
   1. Market Overview
   2. Key Findings
   3. Market Trends
   4. Market Outlook
2. Introduction
   1. Scope of the Report
   2. Research Methodology
   3. Definitions and Assumptions
   4. Acronyms and Abbreviations
3. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
   4. Challenges
4. Global Treatment-Resistant Depression Market
   1. Market Overview
   2. Market Size and Forecast
   3. Market Segmentation
      1. By Drug class
      2. By Route of administration
      3. By Distribution channel
      4. By End-user
      5. By Region
5. Market Segmentation by Drug class
   1. 1. Selective Serotonin Reuptake Inhibitors (SSRIS)
      2. Monoamine Oxidase Inhibitors
      3. Tricyclic Antidepressant
      4. Psychedelics
      5. Others
6. Market Segmentation by Route of administration
   1. 1. Oral
      2. Parenteral
      3. Others
7. Market Segmentation by Distribution channel
   1. 1. Hospital Pharmacy
      2. Online Pharmacy
      3. Retail Pharmacy
8. Market Segmentation by End-user
   1. 1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
9. Regional Analysis
   1. North America
      1. United States
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      2. Canada
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      3. Mexico
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
   2. Europe
      1. United Kingdom
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      2. Germany
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      3. France
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      4. Italy
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      5. Spain
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      6. Rest of Europe
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
   3. Asia Pacific
      1. China
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      2. Japan
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      3. India
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      4. Australia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
         4. South Korea
         5. Market Size and Forecast
         6. Key Trends and Developments
         7. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      5. Rest of Asia Pacific
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
   4. Latin America
      1. Brazil
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      2. Argentina
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      3. Colombia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      4. Rest of Latin America
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
   5. Middle East & Africa
      1. South Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      2. Saudi Arabia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      3. UAE
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
      4. Rest of Middle East & Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Distribution channel and End-user
10. Competitive Landscape
    1. Market Share Analysis
    2. Company Profiles
    3. Pfizer Inc (U.S.)
    4. Mylan N.V. (U.S.)
    5. Novartis AG (Switzerland)
    6. Hikma Pharmaceuticals plc (U.K.)
    7. Aurobindo Pharma (India)
    8. AbbVie Inc. (U.S.)
    9. Melinta Therapeutics, Inc (U.S.)
    10. GSK plc. (U.K.)
    11. Bayer AG (Germany)
11. Strategic Recommendations
12. Appendix
    1. List of Tables
    2. List of Figures
13. References